Bayer sells dermatology unit to Leo Pharma

Denmark-based Leo Pharma yesterday announced it had acquired Bayer’s dermatology unit. The acquisition covers a series of prescription products for the treatment of skin diseases such as acne (Skinoren), fungal infections (Travogen) and a significant number of topical steroid preparations (including Advantan) The acquired unit delivered sales over €280m in 2017 and employs a workforce of 450. The parties did not provide the financial details of the transaction.

(Source: Handelsblatt)